NET TRANSACTION ACCOUNTS:

<table>
<thead>
<tr>
<th>Reservable liability</th>
<th>Reserve requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>$0 to reserve requirement exemption amount ($10.7 million)</td>
<td>0 percent of amount.</td>
</tr>
<tr>
<td>Over reserve requirement exemption amount ($10.7 million) and up to low reserve tranche ($58.8 million)</td>
<td>3 percent of amount.</td>
</tr>
<tr>
<td>Over low reserve tranche ($58.8 million)</td>
<td>$1,443,000 plus 10 percent of amount over $58.8 million.</td>
</tr>
<tr>
<td>Nonpersonal time deposits</td>
<td>0 percent</td>
</tr>
<tr>
<td>Eurocurrency liabilities</td>
<td>0 percent</td>
</tr>
</tbody>
</table>

By order of the Board of Governors of the Federal Reserve System, acting through the Director of the Division of Monetary Affairs under delegated authority, October 21, 2010.

Jennifer J. Johnson, Secretary of the Board.

[FR Doc. 2010–27014 Filed 10–25–10; 8:45 am]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 520, 556, and 558

[Docket No. FDA–2010–N–0002]

Animal Drugs, Feeds, and Related Products; Withdrawal of Approval of New Animal Drug Applications; Aklomide; Levamisole Hydrochloride; Nitromide and Sulfanitran

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations by removing those portions that reflect approval of eight new animal drug applications (NADAs). In a notice published elsewhere in this issue of the Federal Register, FDA is withdrawing approval of these NADAs.

DATES: This rule is effective November 5, 2010.

FOR FURTHER INFORMATION CONTACT: John Bartkowiak, Center for Veterinary Medicine (HFV–212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–276–9079, e-mail: john.bartkowiak@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Fort Dodge Animal Health, a Division of Wyeth Holdings, a Wholly Owned Subsidiary of Pfizer, Inc., 235 East 42d St., New York, NY 10017 has requested that FDA withdraw approval of the eight NADAs listed in Table 1 of this document because they are no longer manufactured or marketed.

<table>
<thead>
<tr>
<th>NADA No.</th>
<th>Product Established name of drug(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NADA 11–141</td>
<td>UNISTAT–2 Type A medicated article nitromide and sulfanitran.</td>
</tr>
<tr>
<td>NADA 14–250</td>
<td>NOVASTAT Type A medicated article aklomide and sulfanitran.</td>
</tr>
<tr>
<td>NADA 34–536</td>
<td>ALKOMIX Type A medicated article aklomide.</td>
</tr>
<tr>
<td>NADA 34–537</td>
<td>NOVASTAT–3 Type A medicated article aklomide, sulfanitran, and roxarsone.</td>
</tr>
<tr>
<td>NADA 35–388</td>
<td>NOVASTAT–W Soluble Powder aklomide, sulfanitran, and roxarsone.</td>
</tr>
<tr>
<td>NADA 39–666</td>
<td>UNISTAT–3 Type A medicated article nitromide, sulfanitran, and roxarsone. levamisole.</td>
</tr>
<tr>
<td>NADA 44–015</td>
<td>TRAMISOL Type A medicated article levamisole.</td>
</tr>
<tr>
<td>NADA 45–455</td>
<td>TRAMISOL Type A medicated article levamisole.</td>
</tr>
</tbody>
</table>

List of Subjects

21 CFR Part 520

Animal drugs.

21 CFR Part 556

Animal drugs, Foods.

21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 520, 556, and 558 are amended as follows:

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

- 1. The authority citation for 21 CFR part 520 continues to read as follows:

§ 520.2320 [Removed]

- 2. Remove § 520.2320.

PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD

- 3. The authority citation for 21 CFR part 556 continues to read as follows:

§ 556.30 [Removed]

- 4. Remove § 556.30.
§ 556.220 [Removed]

5. Remove § 556.220.

§ 556.680 [Removed]

6. Remove § 556.680.

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

7. The authority citation for 21 CFR part 558 continues to read as follows:


§ 558.4 [Amended]

8. In § 558.4, in paragraph (d), in the “Category I” table, remove the listing for “Aklomide”; and in the “Category II” table, remove the listings for “Levamisole”, “Nitromide” immediately followed in sequence by “Sulfanitran”, “Nitromido” immediately followed in sequence by “Sulfanitran” and by “Roxarsone”; “Sulfanitran” immediately followed in sequence by “Aklomide”, and the two listings for “Sulfanitran” immediately followed in sequence by “Aklomide” and by “Roxarsone”.

§ 558.35 [Removed]

9. Remove § 558.35.

§ 558.315 [Removed]

10. Remove § 558.315.

§ 558.376 [Removed]

11. Remove § 558.376.

Dated: October 8, 2010.

Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2010–26979 Filed 10–25–10; 8:45 am]
BILLING CODE 4160–01–P

DEPARTMENT OF THE TREASURY

Internal Revenue Service

26 CFR Part 1

[TD 9340]

RIN 1545–BB64

Revised Regulations Concerning Section 403(b) Tax-Sheltered Annuity Contracts; Correction

AGENCY: Internal Revenue Service (IRS).

TOLLERIS at (202) 622–6060; concerning the regulations, John Tolleris at (202) 622–6060; concerning the regulations as applied to church-related entities, Sherri Edelman or Jason Levine at (202) 283–9634 (not toll-free numbers).

SUPPLEMENTARY INFORMATION:

Background

The final regulations that are the subject of this correction are under section 403(b) of the Internal Revenue Code.

Need for Correction

As published, final regulations (TD 9340) contain errors that may prove to be misleading and are in need of clarification.

List of Subjects in 26 CFR Part 1

Income taxes, Reporting and recordkeeping requirements.

Correction of Publication

Accordingly, 26 CFR part 1 is corrected by making the following correcting amendments:

PART 1—INCOME TAXES

Paragraph 1. The authority citation for part 1 continues to read in part as follows:

Authority: 26 U.S.C. 7805 * * *

§ 1.403(b)–6 Timing of distributions and benefits.

* * * * *

(e) * * *

(5) * * * See also § 1.403(b)–9(a)(5) for additional rules relating to annuities payable from a retirement income account.

* * * * *

Par. 4. Section 1.403(b)–7 is amended by revising the fourth sentence of paragraph (b)(1) to read as follows:

§ 1.403(b)–7 Taxation of distributions and benefits.

* * * * *

(b) * * *

(1) * * * Thus, to the extent that a portion of a distribution (including a distribution from a designated Roth account) would be excluded from gross income if it were not rolled over, if that portion of the distribution is to be rolled over into an eligible retirement plan that is not an IRA, the rollover must be accomplished through a direct rollover of the entire distribution to a plan qualified under section 401(a) or a section 403(b) plan and that plan must agree to separately account for the amount not includible in income (so that a 60-day rollover to a plan qualified under section 401(a) or another section 403(b) plan is not available for this portion of the distribution). * * * * *

Par. 5. Section 1.403(b)–10 is amended by revising the heading of paragraph (b)(3) and adding a heading to paragraph (b)(3)(i) to read as follows:

§ 1.403(b)–10 Miscellaneous provisions.

* * * * *

(b) * * *

(3) Requirements for plan-to-plan transfers—(i) In general. * * *

* * * * *

LaNita Van Dyke,
Chief, Publications and Regulations Branch, Legal Processing Division, Associate Chief Counsel (Procedure and Administration).

[FR Doc. 2010–26979 Filed 10–25–10; 8:45 am]
BILLING CODE 4830–01–P